ライフサイエンスコーパス: cranial irradiation

1 vant chemotherapy alone or chemotherapy with cranial irradiation.

2 All underwent prophylactic cranial irradiation.

3 in metastases, and 8% underwent prophylactic cranial irradiation.

4 gnitive decline in cancer patients receiving cranial irradiation.

5 t of patients with brain tumors had received cranial irradiation.

6 sk-adapted chemotherapy without prophylactic cranial irradiation.

7 l learning and memory impairments induced by cranial irradiation.

8 at may potentially benefit from prophylactic cranial irradiation.

9 Complete responders received prophylactic cranial irradiation.

10 S relapse after a short initial remission or cranial irradiation.

11 f deleterious neurocognitive consequences of cranial irradiation.

12 or adaptive deficits if they do not undergo cranial irradiation.

13 of adding RT to chemotherapy or prophylactic cranial irradiation.

14 inflammation and augments neurogenesis after cranial irradiation.

15 d cyclophosphamide, 58 of whom also received cranial irradiation.

16 chemotherapy drugs, intrathecal therapy, and cranial irradiation.

17 justify future trials including prophylactic cranial irradiation.

18 s associated with intensive chemotherapy and cranial irradiation.

19 y when treated with 23.4 Gy instead of 36 Gy cranial irradiation.

20 r irradiation, we investigated the impact of cranial irradiation (1 and 10 Gy) on a range of micromor

21 T-cell patients who received chemotherapy or cranial irradiation (12 Gy) to prevent overt leukemia in

22 Prophylactic cranial irradiation (12-18 Gy) is given to 2-20% of pati

23 toposide/cisplatin, followed by prophylactic cranial irradiation (30 Gy/15 fractions) if they had a c

24 Cranial irradiation alone rarely results in long-term di

25 y and provide the basis for studies omitting cranial irradiation altogether.

26 Younger age at cranial irradiation and higher dosage were associated wi

27 n = 190, including 99 patients who underwent cranial irradiation), and radiation alone (n = 22).

28 Cancer patients undergoing cranial irradiation are at risk of developing neurocogni

29 hemotherapy will, in all likelihood, replace cranial irradiation as subclinical central nervous syste

30 ession of adult hippocampal neurogenesis via cranial irradiation before drug-taking significantly inc

31 atients who have previously received maximal cranial irradiation but suffer an intracranial recurrenc

32 ive risk-adjusted chemotherapy, prophylactic cranial irradiation can be safely omitted from the treat

33 Because cranial irradiation can cause many acute and late compli

34 Cranial irradiation can lead to long-lasting cognitive i

35 n female sex and cognitive dysfunction after cranial irradiation, cardiovascular outcomes, obesity, r

36 Endocrine deficiencies are common after cranial irradiation, chemotherapy and specific tumors.

37 vel procedure for administering fractionated cranial irradiation (CI) and investigated the incidence

38 clinical trial to test whether prophylactic cranial irradiation could be omitted from treatment in a

39 m lymphoma and those undergoing prophylactic cranial irradiation for systemic malignancies.

40 For patients subjected to cranial irradiation for the control of CNS malignancy, p

41 Cranial irradiation for the treatment of brain cancer el

42 Prophylactic cranial irradiation has been a standard treatment in chi

43 esulting in shortened survival, prophylactic cranial irradiation has been proposed in both small-cell

44 ) who undergo chemotherapy, and prophylactic cranial irradiation, have persistent intrathoracic disea

45 Cranial irradiation impacted neurocognitive outcomes, es

46 that reason, T-ALL patients usually receive cranial irradiation in addition to intensified intrathec

47 ents are a feared consequence of therapeutic cranial irradiation in children as well as adults.

48 ) have been described as a delayed effect of cranial irradiation in children with brain tumors, or a

49 Prophylactic cranial irradiation in near or complete responders to in

50 ied the use of combination chemotherapy plus cranial irradiation in newly diagnosed patients with PCN

51 andomised controlled studies of prophylactic cranial irradiation in oncology patients as well as stud

52 t chemotherapy with and without prophylactic cranial irradiation in patients who undergo complete res

53 al designs of ongoing trials of prophylactic cranial irradiation in stage III NSCLC have taken this i

54 need to eliminate relapse without the use of cranial irradiation in very high-risk patients.

55 ing from hippocampal cytotoxicity induced by cranial irradiation (IR) present a challenge in the trea

56 High-dose methotrexate combined with cranial irradiation is an effective therapeutic approach

57 Although prophylactic cranial irradiation is potentially associated with neuro

58 Cranial irradiation is used routinely for the treatment

59 Cranial irradiation is widely used in cancer therapy, bu

60 frequent result of cancer therapy involving cranial irradiation, leaving patients with marked memory

61 ons were similar in OE and KO mice following cranial irradiation, molecular analyses suggested that t

62 cerebellar tumours but who received neither cranial irradiation nor methotrexate chemotherapy.

63 a meta-analysis have shown that prophylactic cranial irradiation not only reduces the incidence of br

64 t-derived microglia engraftment, rather than cranial irradiation or BMT alone, was responsible for th

65 functions have undergone surgery as well as cranial irradiation or methotrexate treatment.

66 kout (-/-) and wild-type mice received 10 Gy cranial irradiation or sham-treatment.

67 e considered for treatment with prophylactic cranial irradiation, owing to the high frequency of brai

68 Prophylactic cranial irradiation (PCI) has been shown to provide surv

69 y was conducted to determine if prophylactic cranial irradiation (PCI) improves survival in locally a

70 To investigate the role of prophylactic cranial irradiation (PCI) within a trimodality protocol

71 latin and etoposide (PE), early prophylactic cranial irradiation (PCI), and high-dose twice-daily tho

72 ; strata were tumor-node group, prophylactic cranial irradiation policy, and region.

73 Prophylactic cranial irradiation prolongs survival in patients with l

74 al hypothyroidism including ischemic injury, cranial irradiation, psychiatric conditions, or medical

75 t chemotherapy, with or without prophylactic cranial irradiation, relative to no adjuvant therapy for

76 Cranial irradiation remains a frontline treatment for th

77 tive cancer treatment regimens often require cranial irradiation, resulting in lifelong neurocognitiv

78 re older and those treated with reduced-dose cranial irradiation (RRT) of 23.4 Gy.

79 cic radiotherapy in addition to prophylactic cranial irradiation should be considered for all patient

80 agnosis and those who received standard-dose cranial irradiation (SRT) of 36 Gy would have a lower pe

81 st decade, standard therapy has evolved from cranial irradiation to high dose methotrexate-based regi

82 Stratification by previous cranial irradiation was added later as a protocol amendm

83 However, when cranial irradiation was blocked by lead shield, and micr

84 previously would have received prophylactic cranial irradiation was compared with that of 56 histori

85 Cranial irradiation was reserved for patients with highe

86 Cranial irradiation was reserved for the 12% of patients

87 treatment on Total X therapy, and the use of cranial irradiation, which was dose-dependent.

88 ature neurons was strongly reduced following cranial irradiation with (137)Cs, this treatment did not